EyePoint AssistSM

EyePoint Assist is a reimbursement and patient assistance program that is designed to minimize reimbursement risks for ASCs and provide financial assistance to patients.

With EyePoint Assist, you can leave the reimbursement risk behind and implement a single patient protocol.

EyePoint Pharmaceuticals is commited to providing comprehensive support for you and your patients through EyePoint Assist. A representative can provide additional background on how EyePoint Assist can help. Call 1-833-EYEPOINT today (1-833-393-7646), option 3. We are available Monday through Friday, 8:30 am–8:00 pm ET.

Coverage you can count on

EyePoint Assist is committed to helping you access DEXYCU for 100% of your appropriate patients

DEXYCU has a unique permanent J-code effective January 1, 2019

HCPCS CodeShort DescriptionLong Description
J1095Injection, dexamethasone 9%Injection, dexamethasone 9 percent, intraocular, 1 microgram
CMS (Medicare) billing is for a single unit of measure. For DEXYCU 1 unit=1 microgram. Allowable billing for DEXYCU is 517 units.

Providers should use their clinical judgment when selecting codes and should use codes that most accurately represent the product or services delivered. For informational purposes only. EyePoint Pharmaceuticals, Inc., does not guarantee coverage or payment at any level.

Back To Top

Patient Assistance Program

Assistance for financially eligible uninsured, government insured, and commercially insured patients.
Download the Patient Assistance Program form
Back To Top

Product Replacement Program

Your DEXYCU kit will be replaced if the product was mishandled or damaged.
Call 1-833-EYEPOINT (1-833-393-7646), option 1. We are available Monday through Friday, 8:30 AM–8:00 PM ET.

INDICATION AND USAGE

DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Increase in Intraocular Pressure
  • Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
  • Steroids should be used with caution in the presence of glaucoma
Delayed Healing
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation
  • In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids
Exacerbation of Infection
  • The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
  • Use of a corticosteroid in the treatment of patients with a history of herpes simplex requires caution and may prolong the course and may exacerbate the severity of many viral infections
  • Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection
Cataract Progression
  • The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts
ADVERSE REACTIONS
  • The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis
Please click here for full Prescribing Information.

References

1. DEXYCU® (dexamethasone intraocular suspension) 9% full U.S. Prescribing Information. EyePoint Pharmaceuticals, Inc. June 2020. 2. Data on file. EyePoint Pharmaceuticals, Inc. 3. Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial. Ophthalmology. 2018;125(6):799-806. 

INDICATION AND USAGE

DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
None.
DEXYCU, the DEXYCU logo, and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
Verisome is a registered trademark of Ramscor, Inc. EyePoint Assist is a service mark of EyePoint Pharmaceuticals, Inc.
©2022 EyePoint Pharmaceuticals, Inc. All rights reserved. 480 Pleasant Street, Suite B300, Watertown, MA 02472
THIS SITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.
01/2020
US-DEX-2000003
04/2021
US-DEX-2100044
04/2021
US-DEX-2100055
10/2019
US-DEX-1900213
09/2020
US-DEX-2000144
11/2020
US-DEX-2000175
09/2021
US-DEX-2100183
12/2020
US-DEX-2000179
06/2021
US-DEX-2100128
09/2021
US-DEX-2100226
09/2021
US-DEX-2100161
09/2021
US-DEX-2100187
09/2021
US-DEX-2100227